Pivotal bioVenture Partners Investment Advisor LLC

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$251.8M2026 Q3
Positions14
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.91.1%

Pivotal bioVenture Partners Investment Advisor LLC reported 14 positions worth $251.8M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: PCVX (32.2%). Biggest move: new buy OBX ($11.8M).

10 / 14 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PCVXVaxcyte$81.1M32.22%1,425,470——+8.3%
▸ 2 ARQTArcutis Biotherapeutics$26.6M10.58%1,008,174——+2.7%
▸ 3 TRVITrevi Therapeutics$25.0M9.91%1,742,672——-7.2%
▸ 4 AVLNAvalyn Pharma$24.7M9.81%866,792——+4.5%
▸ 5 EVMNEvommune$15.9M6.32%1,926,943——-7.6%
▸ 6 IMNMImmunome$15.8M6.26%732,512——-12.7%
▸ 7 OCSOculis$15.5M6.15%1,658,907———
▸ 8 OBXObsidian Therapeutics$11.8M4.69%860,343———
▸ 9 AVTXAvalo Therapeutics$6.7M2.64%434,033——-49.4%
▸ 10 BRVEBraveheart Bio$6.4M2.55%317,351——-2.9%

Pro Feature

The remaining 4 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Pivotal bioVenture Partners Investment Advisor LLC hold as of Q3 2026?

Pivotal bioVenture Partners Investment Advisor LLC reported 14 positions worth $251.8M in its Q3 2026 13F filing. Largest positions: PCVX (32.2%), ARQT (10.6%), TRVI (9.9%), AVLN (9.8%) and EVMN (6.3%).

What did Pivotal bioVenture Partners Investment Advisor LLC buy in Q3 2026?

New positions: OBX and BRVE. Added to: OCS.

What did Pivotal bioVenture Partners Investment Advisor LLC sell in Q3 2026?

Reduced: ZBIO, ARQT and AVLN. Sold out entirely: RXRX.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.